NASDAQ:IVVD Invivyd Q1 2025 Earnings Report $0.86 +0.02 (+2.76%) As of 05/13/2025 04:00 PM Eastern Earnings HistoryForecast Invivyd EPS ResultsActual EPSN/AConsensus EPS -$0.04Beat/MissN/AOne Year Ago EPSN/AInvivyd Revenue ResultsActual RevenueN/AExpected Revenue$34.45 millionBeat/MissN/AYoY Revenue GrowthN/AInvivyd Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Invivyd Earnings HeadlinesInvivyd Initiates Discovery Program for Monoclonal Antibody Targeting Measles Infection and ProphylaxisMay 13 at 10:35 PM | nasdaq.comInvivyd begins discovery of measles monoclonal antibodyMay 13 at 10:35 PM | investing.comWhy America’s building cathedrals againWhile the media fixates on tariffs and market noise, something historic is unfolding behind the scenes. With backing from the White House and Silicon Valley billionaires, a vast network of AI-powered facilities is taking shape across the country. They’re being called “Cathedrals of Light” — and they hold the keys to nuclear fusion, advanced medicine, and defense breakthroughs. I’ve spent 25 years identifying seismic shifts like this — and I believe this could be the biggest one yet for early investors.May 14, 2025 | Porter & Company (Ad)Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceMay 13 at 7:01 AM | globenewswire.comInvivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for MeaslesMay 12 at 7:01 AM | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) vs. Invivyd (NASDAQ:IVVD) Financial ContrastMay 12 at 2:15 AM | americanbankingnews.comSee More Invivyd Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email. Email Address About InvivydInvivyd (NASDAQ:IVVD), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.View Invivyd ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Upcoming Earnings Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Applied Materials (5/15/2025)Copart (5/15/2025)NetEase (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
